Trade Alert: A Better Way To Play The GLP-1 Trend

A company that can actually profit from last-mile weight loss procedures. Plus, another trade in a profitable stock that looks like it's bottoming out here.

Continuing the GLP-1 Knock-On Effects Theme

Earlier this morning, I wrote about the GLP-1 second-order effects trade—and where I went wrong treating one of Citrini Research’s basket names as a higher-conviction idea than it really was.

In that post, I came to two conclusions:

1) The GLP-1 macro theme is real, but the expression matters.
Citrini was early identifying the initial GLP-1 drug trend, and even if some of his smaller med-tech names didn’t work out, the knock-on effects idea still makes sense: as more patients lose weight from GLP-1 drugs, “last-mile” cosmetic and aesthetic procedures stand to benefit.

2) Our job isn’t to complain about bad trades—it’s to learn from them.
What mattered for us wasn’t that AIRS pulled back, but that we mistook a basket idea for a conviction idea. We corrected that today by finding a stronger fundamental and technical candidate to express the same macro theme.

Today, we’re acting on that analysis—and we’re pairing it with another name we’ve traded profitably this year: a deeply undervalued consumer-internet platform that now looks like it’s carving out a technical bottom ahead of earnings.

Full details are below.

Today’s First Trade

(GLP-1 Second-Order Effects Theme)